Other · developed by Precigen Actobio T1D, LLC
AG019 is an orally administered solid capsule studied in type 1 diabetes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03751007 | Phase 1/2 | Diabetes type1 | Completed | PGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes type1
Updated Oct 25, 2026. Something wrong or missing? Report it on the PGEN page.
See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PGEN catalysts and pipeline →